Printer Friendly

IVAX SUBSIDIARY GRANTED APPROVAL TO MARKET BECLOMETHASONE MET RED DOSE INHALER IN U.K.

 MIAMI, June 7 /PRNewswire/ -- IVAX Corporation (AMEX: IVX) announced today that the United Kingdom Medicines Control Agency granted its wholly-owned subsidiary, Norton Healthcare Limited, approval to market metered dose inhalant forms of beclomethasone dipropionate (50 mcg, 100 mcg and 250 mcg) in the United Kingdom. These products will be marketed by Norton Healthcare's brand name marketing and sales division, Baker Norton Pharmaceuticals, under the trade name "Beclazone".
 A metered dose inhalant form of beclomethasone dipropionate is currently marketed in the United Kingdom by Glaxo under the trademarks "Becotide" and "Becloforte". Baker Norton Pharmaceuticals currently markets a range of branded respiratory products in the United Kingdom and Ireland. These products include the major asthma drugs, Salamol Inhaler (salbutamol 100mcg), Cromogen Inhaler (sodium cromoglycate 5mg), Steri-Neb Salamol 2.5mg and 5mg (salbutamol unit dose nebulizing solution) and Steri-Neb Cromogen (sodium cromoglycate unit dose nebulizing solution).
 IVAX Corporation is a holding company with subsidiaries involved in specialty chemicals, pharmaceuticals and medical diagnostics. IVAX' principal subsidiaries include Baker Norton Pharmaceuticals, Inc., a developer and marketer of unique brand name pharmaceuticals; Norton Healthcare Limited, a leading manufacturer and marketer of generic pharmaceuticals in the United Kingdom, Ireland and other countries; H N Norton Co, a manufacturer of generic pharmaceuticals in the United States; Goldline Laboratories, Inc., a national marketer of generic prescription and over the counter pharmaceuticals in the United States; Baker Cummins Dermatologicals, Inc., a dermatological products company; Flori Roberts, Inc., a skin care and cosmetics company; DVM Pharmaceuticals Inc., a veterinary products company; Baker Cummins, Inc., a marketer of brand name pharmaceuticals in Canada; Diamedix Corporation, a medical diagnostics company; Delta Biologicals S.r.l., a marketer of medical diagnostic tests and instruments in Italy; and IVAX Industries, Inc., a chemical specialties business.
 -0- 6/7/93
 /CONTACT: Richard C. Pfenniger, Jr., senior vice president-legal affairs of IVAX Corporation, 305-590-2309/
 (IVX)


CO: IVAX Corporation; Norton Healthcare Limited; United Kingdom
 Medicines Control Agency ST: Florida IN: MTC SU:


JB-AW -- FL003 -- 5867 06/07/93 09:18 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 7, 1993
Words:333
Previous Article:AUTOMAKERS AND SUPPLIERS TO DEBATE INDUSTRY ISSUES
Next Article:DATAQUEST NAMES HARRIS SEMICONDUCTORMID-SIZE EUROPEAN VENDOR OF THE YEAR FOR 1992
Topics:


Related Articles
IVAX' SUBSIDIARY RECEIVES APPROVAL TO SELL SODIUM CROMOGLYCATE METERED DOSE INHALER IN THE UNITED KINGDOM
IVAX ANNOUNCES JOINT DEVELOPMENT AGREEMENT WITH GLAXO
IVAX ANNOUNCES STRATEGIC ALLIANCE WITH NAPRO BIOTHERAPEUTICS REGARDING TAXOL
IVAX CORPORATION ACQUIRES POLISH PHARMACEUTICAL DISTRIBUTOR
IVAX Announces Restructuring: Company To Focus On Proprietary Drug R&D And To Change Name to IVX BioSciences; Retains Investment Bankers In U.S. And...
IVAX Prevails Over Bristol-Myers Squibb And 3M Company In U.K. Patent Suits
IVAX And Bigmar Sign Exclusive Distribution Agreement
IVAX Prevails Over 3M Company in European Patent Suit.
Dura Pharmaceuticals and Spiros Development Corporation II Announce Initiation of Pivotal Clinical Program for Beclomethasone Spiros.
QVAR(TM) (beclomethasone dipropionate HFA) Inhalation Aerosol Receives FDA Approval for Asthma.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters